Advertisement
Advertisement
RANI
Rani Therapeutics Holdings, Inc. Class A Common Stock
0.97
USDSponsored
+0.03
+3.71%
May 08, 15:58 UTC -4
Closed
After-Market
0.97
0.00
+0.36%
RANI Earnings Reports
Positive Surprise Ratio
RANI beat 15 of 19 last estimates.
79%
Next Report
In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$510.00K
/-$0.04
Implied change from Q4 25 (Revenue/ EPS)
-65.09%
/-42.86%
Implied change from Q1 25 (Revenue/ EPS)
+196.51%
/-81.82%
Rani Therapeutics Holdings, Inc. Class A Common Stock earnings per share and revenue
On Mar 26, 2026, RANI reported earnings of -0.07 USD per share (EPS) for Q4 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached 1.46 million, compared to an expected 5.10 million, with a -71.35% difference. The market reacted with a -24.94% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.04 USD, with revenue projected to reach 510.00 thousand USD, implying an decrease of -42.86% EPS, and decrease of -65.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Rani Therapeutics Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Rani Therapeutics Holdings, Inc. Class A Common Stock reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $1.46M, -71.35% below expectations.
How did the market react to Rani Therapeutics Holdings, Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved down -24.94%, changed from $1.08 before the earnings release to $0.81 the day after.
When is Rani Therapeutics Holdings, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Rani Therapeutics Holdings, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Rani Therapeutics Holdings, Inc. Class A Common Stock is expected to report EPS of -$0.04 and revenue of $510.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement